Roche Diagnostics Corp.

Roche Diagnostics Corp. is the U.S. operating subsidiary of Roche Diagnostics, the in-vitro diagnostics (IVD) division of Roche Holding AG (SIX: ROG; OTC: RHHBY), the Basel, Switzerland–based pharmaceutical and diagnostics group founded in 1896. Roche Diagnostics Corp.'s North American headquarters is in Indianapolis, Indiana, employing roughly 4,800 people there and across U.S. field roles, per a company brochure. Roche Diagnostics is a wholly owned division of Roche Holding, which reports more than 103,000 employees worldwide (2024). Roche's Diagnostics division is a global leader in IVD.

Products / operations. Roche Diagnostics develops and manufactures diagnostic tests, instruments, and digital solutions for disease prevention, screening, diagnosis, and monitoring. Core lines include clinical chemistry and immunoassays (the cobas platform, Elecsys assays), molecular diagnostics (cobas, LightCycler), tissue/pathology diagnostics (BenchMark, Ventana), point-of-care and near-patient testing (cobas liat, CoaguChek), next-generation sequencing, blood screening, laboratory automation, and digital workflow tools (navify). Diabetes self-testing falls under Roche Diabetes Care. It is an operating company, not an NPE.

Litigation posture. The tracked data show one case, in which Roche Diagnostics is a defendant only (0 as plaintiff, 1 as defendant) — the classic profile of an operating company targeted by an assertion rather than a patent aggressor. The single suit is Troll Busters LLC v. Roche Diagnostics GmbH et al., filed 2011-01-10 in the U.S. District Court for the Southern District of California (Judge Irma E. Gonzalez; Magistrate William V. Gallo). The plaintiff name suggests a patent-assertion entity; the case sits in California, not a plaintiff-friendly Texas venue. No other tracked appearances exist.

I could not verify the specific patents or outcome of that case, nor current diagnostics-segment revenue or employee counts beyond the figures above; those details are unconfirmed here.